Arialys Therapeutics

Executive Summary

Arialys Therapeutics is a San Diego-based biotechnology company developing novel antibody therapeutics for severe autoimmune and inflammatory disorders of the central nervous system. Founded in 2020, the company's lead candidate precisely targets a key mediator of neuroinflammation, aiming to halt disease progression in conditions with limited treatment options, such as autoimmune encephalitis and neuromyelitis optica spectrum disorder. With $58 million in funding, Arialys has advanced its lead program into Phase 1 clinical development, leveraging its proprietary platform to engineer antibodies with high specificity and blood-brain barrier penetration. The company's approach addresses a significant unmet need in neuroinflammation, where current therapies often provide symptomatic relief but fail to modify disease course. Arialys’s focus on antibody-based precision medicine positions it uniquely in the competitive landscape of neuroscience and immunology.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim safety and biomarker data readout70% success
• Q2 2027Initiation of Phase 2 trial in autoimmune encephalitis50% success
• Q1 2027Potential strategic partnership or licensing deal40% success